The investigators hypothesize that subcutaneous pramlintide as an adjunct to mealtime insulin
immediately prior to meals can significantly reduce post-prandial glucose concentrations
compared with mealtime insulin alone in children with type 1 diabetes.
This is a 36 day, randomized, two-arm, open-label study with a treatment arm (taking
pramlintide before all meals) and a control arm (diabetes regimen as usual).